Plant-derived Recombinant Human Serum Albumin Injection (HY1001 project) Clinical Trials Phase II Data Progress Report
September 26th, China Health Ecology Organization (CHEO) was grandly held in Bo’ao. At the Pharmaceutical Innovation and Capital Market sub-forum of the China Pharmaceutical Innovation Ecological conference (CPIE), which is the one of the six core summits of CHEO, Professor Daichang Yang , President, General Manager and Chief Scientist of Wuhan Healthgen Biotechnology Corp, gave a detailed report on the technical advancement of the rice endosperm specific expression platform (OryzHiExp), and the series of bio-innovative biopharmaceuticals developed by this platform, represented by plant-derived recombinant human serum albumin injection (Project HY1001).
Project HY1001 is undergoing the clinical trial phase II. As of the report date, the enrollment data showed that all of the designed clinical primary or secondary endpoints were reached, demonstrating the great safety and efficacy.
During the conference, Healthgen Biotech’s technical platform and multiple projects have received extensive attention from many investors. Among them, Jointown Pharmaceutical Group Co., Ltd. and Yunnan Baiyao Group Co.,Ltd. showed strong interest and willingness to invest.
